LVEDD

AcronymDefinition
LVEDDLeft Ventricular End Diastolic Diameter
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
No statistically significant difference of LVEDD was found between the two groups (MD = -2.01, 95% CI [-4.72, 0.70], p = 0.15, Figure 4).
Conventional Echocardiographic Findings SSc (n=47) HC (n=20) p LVEDD (cm) 4.95[+ or -]0.22 4.91[+ or -]0.17 0.45 LVESD (cm) 3.09[+ or -]0.2 3.05[+ or -]0.2 0.51 EF (%) 60.1[+ or -]2.18 60.7[+ or -]1.83 0.30 RAD (cm) 3.75[+ or -]0.27 3.49[+ or -]0.34 0.001 RVD (cm) 2.34[+ or -]0.18 2.19[+ or -]0.15 0.002 TAPSE (cm) 2.02[+ or -]0.33 2.96[+ or -]0.51 0.0001 SPAP (mmHg) 30.78[+ or -]4.83 23.35[+ or -]3.23 0.001 TRV (m/sn) 2.62[+ or -]0.31 2.02[+ or -]0.19 0.001 LVEDD: left ventricular end-diastolic diameter; LVESD: left ventricular end-systolic diameter; EF: ejection fraction; RAD: right atrial diameter; RVD: right ventricular diameter; TAPSE: tricuspidal annular plane systolic excursion; SPAP: systolic pulmonary artery pressure Table 3.
Furthermore, LVEDD and LVEDV significantly decreased following down-regulation of YAP to inhibit cardiac matrix remodeling (Figure 4I and J).
Age, gender, body weight, height, body mass index, systolic and diastolic pressures, LA diameter, LVEDd, LVEDs and LV EF were similar in both groups (p>0.05) (Table 1).
To explore the predictors of all-cause mortality, cardiovascular event mortality, and re-hospitalization event, multivariable Cox regression models with forward stepwise approach were constructed with age, sex, BMI, hypertension, previous stroke, coronary heart disease, smoking, NYHA class, LVEF, LVEDD, FPG, eGFR, and medical and device implantation treatments as predictive variables, respectively.
Deviation LVEDD 41.82 4.83 LVESD 27.28 4.82 IVSD 9.44 1.38 PWD 9.40 1.35 EDV 76.58 22.39 ESV 29.38 13.19 EF 61.74 9.03 FS 33.38 6.00 LV_MASS 90.64 37.18 MAPSE 22.38 4.05 Average Systolic TDI 9.84 1.54 Mean Std.
LVRR was defined as an absolute improvement of LVEF of [greater than or equal to] 10% to a final value of [greater than or equal to] 35%, accompanied by a decrease in LVEDD of at least 10%, as assessed by echocardiography at 12 months of follow-up.
All the examined referees had an LVEDD lower than 60 mm and a parietal thickness (IVSd or LVPWd) lower than 14 mm.
Spirometric and echocardiographic parameters of the studied children Character Spirometric indices: * [FEV.sub.1] (L) 1.64[+ or -]0.54 * FEV% 93.08[+ or -]5.53 * FVC (L) 1.86[+ or -]0.59 * FVC% 92.83[+ or -]6.41 * [FEV.sub.1]/FVC 88.33[+ or -]4.4 * PEFR (L) 3.42[+ or -]1.13 Echocardiographic data: * LVEDD (mm) 39.5[+ or -]5.9 * LVESD (mm) 24.6[+ or -]4.9 * EF (%) 58.2[+ or -]5.7 * s PAP (mmHg) 40.9[+ or -]8.8 ** RV Sm (cm/seconds) 10.2[+ or -]1.5 No.
The transthoracic echocardiography revealed global dilation of the heart, predominantly left cavities (LA = 54 mm, LVEDD = 61 mm, LVESD = 55 mm, LVEDV= 270 ml, LVESV= 210 ml), moderate mitral regurgitation (MR) secondary to left ventricular dilation.
Four weeks after implantation with osmotic mini pumps, mice were anesthetized with 2% isoflurane, and the structure and function of the left ventricle (LV), including the heart rate (HR), LV end-systolic diameter (LVESD), LV end-diastolic diameter (LVEDD), LV posterior wall thickness (LVPWD), end-diastolic ventricular septal thickness (IVSD), ejection fraction (EF), and fractional shortening (FS), were measured by the MyLab[TM] 30CV ultrasound system (Esaote SpA, Genoa, Italy) equipped with a 10 MHz linear array ultrasound transducer.